Grand Mount Capital
Overview
Grand Mountain (or Mount, the sources are inconsistent) is a venture capital firm jointly established by a professional investment team and state-owned assets based in Shanghai, China. The firm specializes in investing in the fields of biopharmaceuticals, medical devices, healthcare services, and diagnostics.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Infinigence AI | May 2026 | Series B | Lead |
| PixVerse | Jul 2026 | Series C | Co-investor |
| Neurophth | Feb 2021 | Series B | Co-investor |
| Bioeast Biotech | Sep 2021 | Series A | Co-investor |
| HiFiBiO Therapeutics | Jun 2021 | Series D | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Grand Mount Capital based?
Grand Mount Capital is headquartered in Shanghai, Shanghai, China.
When was Grand Mount Capital founded?
Grand Mount Capital was founded in 2019.
How many portfolio companies does Grand Mount Capital have?
Grand Mount Capital has 7 portfolio companies in Caplight's dataset.
What are some companies in Grand Mount Capital's portfolio?
Portfolio companies visible on Caplight include Infinigence AI, PixVerse, Neurophth, Bioeast Biotech, HiFiBiO Therapeutics.
What was Grand Mount Capital's most recent investment shown here?
Grand Mount Capital's most recent investment in this portfolio sample was in PixVerse in 2026.
What sectors does Grand Mount Capital focus on?
Grand Mount Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Media, Entertainment & Gaming, Enterprise Software, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does Grand Mount Capital focus on?
Grand Mount Capital typically invests at the Mid stage.
What is Grand Mount Capital's AUM?
Grand Mount Capital's assets under management are estimated between $100.0M and $250.0M.